Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calcitriol + cisplatin + docetaxel
- Development stage
- Phase 2
- Lead developer
- Paratek Pharmaceuticals
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of three drugs—calcitriol (the active form of vitamin D3), cisplatin (a platinum-based chemotherapy agent), and docetaxel (a taxane-class chemotherapy drug). Calcitriol acts as a hormone with antiproliferative effects on cancer cells, modulating cell growth, differentiation, and apoptosis. Cisplatin forms DNA crosslinks that inhibit DNA synthesis and function, leading to cell death. Docetaxel stabilizes microtubules to prevent cell division. Preclinical studies have shown synergistic antiproliferative effects when calcitriol is combined with cisplatin or docetaxel. This combination has been investigated in phase I/II clinical trials for advanced non-small-cell lung cancer (NSCLC) to determine safety, dosing, pharmacokinetics/pharmacogenomics correlations (notably CYP24A1 SNPs), and preliminary efficacy[1]. The regimen has also been explored in prostate cancer settings for its potential to enhance antitumor activity[3][4][5].
- Other names
- calcitriol and cisplatin and docetaxel1,25-dihydroxyvitamin D3 + cisplatin + docetaxel
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))VDR (Vitamin D receptor)
Beyond the preview
Go deeper on calcitriol + cisplatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calcitriol + cisplatin + docetaxel.